

Special Issue

Challenges to Developing New Vaccines and Improving Existing Platforms

Message from the Guest Editor

The science community faces significant challenges in developing new vaccines and enhancing existing vaccine platforms for infectious diseases and cancer. This Special Issue will address the following aspects of vaccines and their development:

- Vaccine delivery for human and animal species for infectious diseases and cancer.
- Advances in vaccine design that provide broad protection and stimulate humoral and cellular immunity.
- Combining inactivated and subunit vaccines with long-acting adjuvants to maximize their effectiveness.
- Development of novel assays, e.g., omics-based approaches, to evaluate comprehensive and early responses to vaccination.
- Overcoming obstacles in developing flavivirus vaccines, e.g., dengue viruses, addressing virus serotypes, and preventing antibody-dependent enhancement.

Guest Editor

Prof. Dr. S. Louise Cosby

1. School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast BT9 7BL, UK
2. Virology, Veterinary Sciences Division, Agri-Food and Biosciences Institute, Belfast BT4 3SD, UK

Deadline for manuscript submissions

31 January 2027



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/212050

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).